Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Terns Pharmaceuticals Inc shares valued at $3,640,480 were purchased by AMY BURROUGHS on Jan 15 ’26. At $37.18 per share, AMY BURROUGHS acquired 97,915 shares.
Also, Burroughs Amy L. sold 71,339 shares, netting a total of over 2,718,230 in proceeds. Following the sale of shares at $38.10 each, the insider now holds 138,976 shares.
Before that, Kuriakose Emil had sold 1,155 shares from its account. In a trade valued at $44,552, the Chief Medical Officer traded Terns Pharmaceuticals Inc shares for $38.57 each. Upon closing the transaction, the insider’s holdings decreased to 1,155 shares, worth approximately $1.86 million.
As published in a research note from H.C. Wainwright on November 04, 2025, Terns Pharmaceuticals Inc [TERN] has been rated up from a Neutral to a Buy and the price target has been revised to $20. Analysts at William Blair upgraded the stock from ‘”a Mkt perform”‘ to ‘”an Outperform”‘ outlook in a report released in early November. As of October 15, 2025, Truist has initiated its “Buy” rating for TERN. Earlier on September 17, 2025, Barclays initiated its rating. Their recommendation was “an Overweight” for TERN stock.
Analyzing TERN Stock Performance
On last trading session, Terns Pharmaceuticals Inc [NASDAQ: TERN] plunged -0.54% to $36.98. The stock’s lowest price that day was $36.49, but it reached a high of $37.77 in the same session. During the last five days, there has been a drop of approximately -2.09%. Over the course of the year, Terns Pharmaceuticals Inc shares have jumped approximately 709.19%.
Support And Resistance Levels for Terns Pharmaceuticals Inc (TERN)
RSI (Relative Strength Index) is 50.70 on the 14-day chart, showing neutral technical sentiment.
Is Terns Pharmaceuticals Inc subject to short interest?
Stocks of Terns Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 6.67 million shares to 15.45 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 8.78 million shares. A jump of 43.17% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.41 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.41.
Which companies own the most shares of Terns Pharmaceuticals Inc (TERN)?
In terms of Terns Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 56 in the next 12 months, up nearly 50.62% from the previous closing price of $37.18. Analysts anticipate Terns Pharmaceuticals Inc stock to reach 70 by 2026, with the lowest price target being 35. In spite of this, 5 analysts ranked Terns Pharmaceuticals Inc stock as Buy at the end of 2026.
